Skip to main
BCAX

BCAX Stock Forecast & Price Target

BCAX Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 36%
Buy 36%
Hold 27%
Sell 0%
Strong Sell 0%

Bulls say

Bicara Therapeutics is a clinical-stage biopharmaceutical company with a strong potential in the market for their lead product ficerafusp alfa, which is a bifunctional antibody targeting EGFR and TGF-b. The company's recent earnings report highlighted impressive progress in their pivotal study for the drug in 1L R/M HNSCC, with a potential for accelerated approval by mid-2027. The company's leadership transition and continued investments in development and commercial buildout further demonstrate their confidence in the potential of ficerafusp alfa. With several upcoming data readouts and a strong financial position, there is room for the stock to continue its growth trajectory.

Bears say

Bicara Therapeutics is facing intense competition with other biopharmaceutical companies that are already demonstrating strong activity in similar therapies, potentially limiting their first to market advantage. They are also exploring a smaller addressable market by targeting right-sided CRC and considering potential RAS inhibitor combinations, which may pose challenges and require further development, delaying potential profits. Additionally, they acknowledge the need for careful consideration of potential synergistic toxicity before committing to certain strategies, indicating potential risks and uncertainties for their product ficerafusp alfa.

BCAX has been analyzed by 11 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 36% recommend Buy, 27% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bicara Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bicara Therapeutics Inc (BCAX) Forecast

Analysts have given BCAX a Buy based on their latest research and market trends.

According to 11 analysts, BCAX has a Buy consensus rating as of Aug 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32.64, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32.64, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bicara Therapeutics Inc (BCAX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.